CoreRx Acquires Nucleo Life Sciences

CoreRx Acquires Nucleo Life Sciences

Acquisition Creates Unparalleled East / West Coast Development Services Presence in the US

CLEARWATER, FL, May 24, 2021, CoreRx, Inc. announced today the acquisition of Nucleo Life Sciences, a boutique CDMO based in San Rafael, California. Nucleo complements CoreRx’s development services and capabilities and provides a local site on the US West Coast for development services customers.

Nucleo enhances CoreRx’s offering in Fast-to-Clinic (ClinicFirst™) dosage form development, and enhanced formulations for molecules with challenging target profiles. Nucleo’s Fast-to-Clinic approach is differentiated in the market by utilizing formulation expertise and know-how combined with highly scalable equipment. For molecules facing bioavailability enhancement challenges, Nucleo has industry leading capabilities including spray-dried dispersions (SDD) and its proprietary NucleLoad™ technology.

CoreRx CEO Todd Daviau stated, “I’d like to congratulate the Nucleo team on building an exciting business, and I am thrilled to be joining forces. Nucleo is a perfect complement to the development capabilities of CoreRx. We are impressed by their presence on the US West Coast and are looking to accelerate growth of our combined business in the US on both coasts and beyond. In addition, we expect to provide our customers with seamless tech transfers for programs starting in San Rafael and scaling up with clinical and commercial production in Clearwater.”

Mark Menning, CEO of Nucleo Life Sciences, commented on the acquisition by saying, “It is an exciting opportunity for Nucleo to join the CoreRx team. The cultures of Nucleo and CoreRx are very similar – a strong customer focus and a commitment to industry-leading technology solutions. Together Nucleo and CoreRx are well positioned to support customers during all phases of clinical development through commercial manufacturing as a premier high-quality CDMO”.

Mark Menning will join CoreRx and take on the newly created role of Chief Scientific Officer.

Majority owner NovaQuest Private Equity, its affiliates, and certain other minority shareholders supported CoreRx in the acquisition.


About CoreRx, Inc.

CoreRx is a Contract Development Manufacturing Organization (CDMO) with capabilities to support clinical and commercial manufacturing needs. Our state-of-the art facilities support customers’ supply chain needs, and our integrated offerings provide comprehensive services for the development, manufacturing, and testing of solid, liquid and semi-solid dosage forms.

Keep on top of new developments at CoreRx and throughout the drug development industry by following– For more information, please visit